SYI Synvista Therapeutics,

- Presentation to be Webcast - MONTVALE, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX:SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the upcoming 2008 BIO Investor Forum on Thursday, October 30, at 8:30 a.m. Pacific Time. The event will be held October 29th - 31st at the Palace Hotel in San Francisco, California. Dr. Berkowitz will discuss the company's planned commercialization of its haptoglobin test kit for diabetes and ongoing Phase 2 initiatives for alagebrium in heart failure and diabetic nephropathy. He will also provide an update of recent milestones. The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com/. Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event. Note to Attendees: Synvista will be available for one-on-one meetings. Please arrange through BIO or by calling Kim Sutton Golodetz at Lippert/Heilshorn & Associates at 212-838-3777. About Synvista Therapeutics Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's Web site at http://www.synvista.com/. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov/. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. DATASOURCE: Synvista Therapeutics, Inc. CONTACT: Synvista Therapeutics, Inc., +1-201-934-5000, ; or Investor Relations, Kim Sutton Golodetz of Lippert/Heilshorn & Associates, +1-212-838-3777, Web Site: http://www.synvista.com/

Copyright